The long noncoding RNA-H19/miRNA-93a/ATG7 axis regulates the sensitivity of pituitary adenomas to dopamine agonists

Area of Science:

• Endocrinology
• Molecular Biology
• Oncology

Background:

• Dopamine agonists (DAs) are first-line treatment for prolactinomas.
• Long noncoding RNA H19 (H19) is downregulated in pituitary adenomas and linked to tumor progression.
• The role of H19 in DA treatment for prolactinomas remains unclear.

Purpose of the Study:

• To investigate the synergistic effect of H19 and DA treatment in prolactinomas.
• To elucidate the underlying molecular mechanism of H19 in DA treatment.
• To identify H19 as a potential therapeutic target for prolactinomas.

Main Methods:

• In vitro and in vivo experiments on prolactinoma cells.
• Analysis of H19, miR-93a, and ATG7 expression.
• Luciferase reporter assays to confirm binding sites.

Main Results:

• H19 demonstrated a synergistic effect with DA treatment in prolactinomas.
• H19 promotes ATG7 expression by inhibiting miR-93a.
• miR-93a directly targets and regulates ATG7 mRNA expression.
• Low miR-93 expression correlates with DA resistance.

Conclusions:

• The H19-miR-93-ATG7 axis plays a crucial role in DA treatment of prolactinomas.
• This pathway represents a potential therapeutic strategy for human prolactinomas.